 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...167168169170171172173174175176177178179 |
- dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
Enrollment open, Metastases: Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Nov 14, 2011
P2, N=60, Recruiting, Sponsor: ParinGenix
Not yet recruiting --> Recruiting
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: GAIN-1: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 9, 2011
P2, N=10, Active, not recruiting, Sponsor: University of Florida
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 30, 2011
P2, N=40, Recruiting, Sponsor: City of Hope Medical Center
- | dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
New P2 trial, Metastases: Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Oct 26, 2011
P2, N=60, Recruiting, Sponsor: ParinGenix
- | carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion: Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer (clinicaltrials.gov) - Oct 10, 2011
P2, N=40, Completed, Sponsor: Southeastern Gynecologic Oncology
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| albumin-bound paclitaxel / Generic mfg.
Trial completion: SNAPIST-III: Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (clinicaltrials.gov) - Oct 5, 2011
P1/2, N=112, Completed, Sponsor: Celgene Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- chloroquine phosphate / Generic mfg.
New P2 trial, Combination therapy, Metastases: Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) (clinicaltrials.gov) - Oct 2, 2011
P2, N=47, Recruiting, Sponsor: The Methodist Hospital System
- Herceptin (trastuzumab) / Roche
New P2 trial: Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab (clinicaltrials.gov) - Sep 8, 2011
P2, N=45, Active, not recruiting, Sponsor: Osaka Medical College
- ||||| Odomzo (sonidegib) / Sun Pharma
New P1/2 trial, Combination therapy: Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 8, 2011
P1/2, N=52, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- albumin-bound paclitaxel / Generic mfg.
Trial completion: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 22, 2011
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany) (clinicaltrials.gov) - Aug 11, 2011
P2, N=66, Terminated, Sponsor: German Breast Group
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Aug 7, 2011
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center